Published in Hum Mol Genet on May 11, 2012
FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep (2012) 1.50
Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (2013) 1.32
Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med (2013) 1.22
ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun (2015) 1.09
Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice. Neurobiol Aging (2013) 0.93
Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics (2014) 0.87
Genetic circuitry of Survival motor neuron, the gene underlying spinal muscular atrophy. Proc Natl Acad Sci U S A (2013) 0.86
Morphological characteristics of motor neurons do not determine their relative susceptibility to degeneration in a mouse model of severe spinal muscular atrophy. PLoS One (2012) 0.85
Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis. Cell Death Dis (2013) 0.84
Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci (2016) 0.83
Genetic Modifiers for Neuromuscular Diseases. J Neuromuscul Dis (2015) 0.77
Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides. PLoS One (2016) 0.77
Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. Sci Rep (2016) 0.77
Nuclear localization of SMN and FUS is not altered in fibroblasts from patients with sporadic ALS. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.76
Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease. Cell Rep (2017) 0.75
Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: a role for CWC22. Dis Model Mech (2017) 0.75
Functional interaction between FUS and SMN underlies SMA-like splicing changes in wild-type hFUS mice. Sci Rep (2017) 0.75
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science (1994) 18.08
Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41
Directed differentiation of embryonic stem cells into motor neurons. Cell (2002) 9.76
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol (2004) 6.26
Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet (1997) 6.08
Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci (2007) 6.08
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci (2008) 5.89
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet (2005) 5.23
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
A novel nuclear structure containing the survival of motor neurons protein. EMBO J (1996) 4.72
Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci (2006) 3.06
Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet (2008) 2.82
Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (1995) 2.79
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.73
Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron (2005) 2.73
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods (1997) 2.04
Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes Dev (2001) 2.03
Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci (2008) 1.91
The relationship between SMN, the spinal muscular atrophy protein, and nuclear coiled bodies in differentiated tissues and cultured cells. Exp Cell Res (2000) 1.89
The Cajal body: a meeting place for spliceosomal snRNPs in the nuclear maze. Chromosoma (2006) 1.81
Cajal bodies and coilin--moving towards function. J Cell Biol (2002) 1.69
SMN1 gene duplications are associated with sporadic ALS. Neurology (2012) 1.62
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest (2011) 1.62
The Cajal body. Biochim Biophys Acta (2008) 1.61
WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies. PLoS Biol (2010) 1.57
Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet (2000) 1.50
Spinal muscular atrophy: a timely review. Arch Neurol (2011) 1.48
Temporal requirement for high SMN expression in SMA mice. Hum Mol Genet (2011) 1.44
Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep (2006) 1.42
New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 1.29
Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology (2001) 1.19
SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology (2006) 1.15
SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology (2005) 1.14
Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis (2009) 1.02
The survival motor neuron (SMN) protein: effect of exon loss and mutation on protein localization. Neurogenetics (2000) 0.96
Nuclear localization of human SOD1 and mutant SOD1-specific disruption of survival motor neuron protein complex in transgenic amyotrophic lateral sclerosis mice. J Neuropathol Exp Neurol (2012) 0.94
SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. Biochem Biophys Res Commun (2007) 0.90
SMN1 gene study in three families in which ALS and spinal muscular atrophy co-exist. Neurology (2002) 0.88
The threat of instability: neurodegeneration predicted by protein destabilization and aggregation propensity. PLoS Biol (2008) 0.86
Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology (2002) 0.82
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet (2005) 5.23
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol (2003) 3.40
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol (2003) 2.94
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet (2008) 2.82
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol Genet (2008) 2.35
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15
Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS model. Proc Natl Acad Sci U S A (2006) 2.10
CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem (2005) 2.08
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci (2008) 1.92
The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A (2006) 1.90
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.87
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol (2005) 1.83
Genetic clues to the pathogenesis of Parkinson's disease. Nat Med (2004) 1.76
Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci (2003) 1.74
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A (2005) 1.68
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest (2011) 1.62
Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H. Am J Hum Genet (2007) 1.58
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol (2002) 1.52
Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene. J Neurosci (2010) 1.49
Classic and new animal models of Parkinson's disease. J Biomed Biotechnol (2012) 1.45
The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A (2009) 1.43
Mitophagy: the latest problem for Parkinson's disease. Trends Mol Med (2010) 1.41
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci (2005) 1.40
Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res (2009) 1.35
Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci (2006) 1.30
Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis (2009) 1.29
Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life (2003) 1.26
Pathogenic role of glial cells in Parkinson's disease. Mov Disord (2003) 1.25
Spinal muscular atrophy: new and emerging insights from model mice. Curr Neurol Neurosci Rep (2010) 1.21
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.21
Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci (2012) 1.19
Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci (2006) 1.19
Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord (2012) 1.19
A tale on animal models of Parkinson's disease. Mov Disord (2011) 1.18
Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum Mol Genet (2011) 1.18
Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest (2003) 1.17
Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci (2002) 1.17
A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol (2011) 1.16
Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J Neurosci (2003) 1.16
α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci (2014) 1.13
Pathogenesis of Parkinson's disease. Mov Disord (2012) 1.13
Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci (2004) 1.13
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol (2006) 1.10
Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med (2012) 1.10
Animal models of Parkinson's disease. Parkinsonism Relat Disord (2012) 1.07
Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest (2014) 1.06
Pink1 kinase and its membrane potential (Deltaψ)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode. J Biol Chem (2012) 1.06
Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron (2012) 1.05
Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med (2005) 1.04
Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy. PLoS One (2012) 1.03
L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann Neurol (2004) 1.01
Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol Cell Neurosci (2012) 0.98
Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. EMBO Rep (2013) 0.98
Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol (2006) 0.96
The Role of the Innate Immune System in ALS. Front Pharmacol (2012) 0.95
Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. J Neurochem (2003) 0.95
Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol (2010) 0.94
Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells. J Neurosci (2006) 0.93
What can pluripotent stem cells teach us about neurodegenerative diseases? Nat Neurosci (2010) 0.93
PINK1/Parkin direct mitochondria to autophagy. Autophagy (2010) 0.92
D-β-hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One (2011) 0.92
Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med (2009) 0.91
PINK1 points Parkin to mitochondria. Autophagy (2010) 0.91
Neuroinflammation and Parkinson's disease. Handb Clin Neurol (2007) 0.90
Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem (2007) 0.90
The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy. Neurosci Lett (2008) 0.89
Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics (2014) 0.87
The rotenone model of Parkinson's disease. Trends Neurosci (2003) 0.86
Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol (2015) 0.84
Glial cell response: A pathogenic factor in Parkinson's disease. J Neurovirol (2002) 0.83
Mitophagy in cells with mtDNA mutations: being sick is not enough. Autophagy (2012) 0.83
Intrabody and Parkinson's disease. Biochim Biophys Acta (2008) 0.80